Zhenyu Q. Jiang
71 Xinmin Street
Changchun, 130021, China
Changchun, 130021, China
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 65 publications
Efficacy and safety of Xeligekimab (GR1501) in the treatment of axial Spondyloarthritis: Results from a Phase II clinical trial.
Journal: Rheumatology and immunology research
Published: October 31, 2025
Xeligekimab, an Interleukin-17A Antagonist for Active Radiographic Axial Spondyloarthritis in Chinese Patients: 16- and 48-Week Results from a Phase III, Randomized, Double-Blind, Placebo-Controlled Study.
Journal: BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy
Published: October 28, 2025
Efficacy and safety of Janus kinase 1/2 inhibitor KL130008 in active rheumatoid arthritis: a randomized, double-blind, placebo-controlled phase II trial.
Journal: BMC medicine
Published: August 07, 2025
Vunakizumab in patients with active psoriatic arthritis: a multicentre, randomized, double-blind, placebo-controlled, phase 2 study.
Journal: Rheumatology (Oxford, England)
Published: May 30, 2025
Efficacy and Safety of Ivarmacitinib, a Selective JAK1 Inhibitor, in Patients With Active Ankylosing Spondylitis: Results From an Adaptive Seamless Phase 2/3 Trial.
Journal: Arthritis & rheumatology (Hoboken, N.J.)
Published: January 03, 2025
Efficacy and Safety of Dotinurad Versus Febuxostat for the Treatment of Gout: A Randomized, Multicenter, Double-Blind, Phase 3 Trial in China.
Journal: Arthritis & rheumatology (Hoboken, N.J.)
Published: December 25, 2024
Chinese guidelines for the diagnosis and treatment of rheumatoid arthritis: 2024 update.
Journal: Rheumatology and immunology research
Published: October 26, 2024
Chinese Registry of Rheumatoid Arthritis (CREDIT) VI: Temporal Trends in Patients With Early Rheumatoid Arthritis and Moderate-To-Severe Disease Activity - A Multicenter Cohort Study of Treatment Strategies and Outcomes.
Journal: International journal of rheumatic diseases
Published: October 22, 2024
Ivarmacitinib, a selective Janus kinase 1 inhibitor, in patients with moderate-to-severe active rheumatoid arthritis and inadequate response to conventional synthetic DMARDs: results from a phase III randomised clinical trial.
Journal: Annals of the rheumatic diseases
Published: July 08, 2024
Risk prediction of new-onset thrombocytopenia in patients with systemic lupus erythematosus: a multicenter prospective cohort study based on Chinese SLE treatment and research group (CSTAR) registry.
Journal: Arthritis research & therapy
Published: June 07, 2024
Systemic lupus erythematosus related thrombotic microangiopathy: A retrospective study based on Chinese SLE Treatment and Research Group (CSTAR) registry.
Journal: Chinese medical journal
Published: April 20, 2024
Last Updated: 09/26/2026